Garuda was founded and is supported by experts in blood stem cell and bone marrow transplants as well as leaders with expertise in bringing transformative medicines to patients.
Chief Executive Officer
Garuda Therapeutics, Inc.
Partner
Aisling Capital
Managing Partner
OrbiMed
Director
Northpond Ventures
Co-Founder and CEO
National Resilience, Inc.
Former CEO
Decibel Therapeutics
Managing Director at Cormorant Asset Management
Co-Director, Harvard Stem Cell Institute
Gerald and Darlene Jordan Professor of Medicine, Harvard University
Investigator, Howard Hughes Medical Institute
Founder & Director, Children’s Research Institute at UT Southwestern Medical Center
Professor of Medicine, Stanford University
Former Chief of the Division of Blood and Marrow Transplantation, Stanford University
Executive Director, Connell and O’Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Head, Division of Hematologic Malignancies &
Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center
Professor of Hematology-Oncology, University of Pennsylvania School of Medicine
Assistant Professor of Pediatrics, Stanford University School of Medicine
Distinguished McKnight Professor of Pediatrics, University of Minnesota
Harvard Medical School
January
9
2024
CAMBRIDGE, Mass. January 9, 2024 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-founder, President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 9:30 am PT. read more →
We are seeking team members who share our passion for science, work ethic, and sense of urgency to improve patients’ lives.